Pub Date : 2026-01-01Epub Date: 2026-01-18DOI: 10.1177/03913988251409049
Yusriandi Ramadhan, Rahadian Indarto Susilo, Nur Setiawan Suroto, Dyah Fauziah, Asra Al Fauzi, Achmad Fahmi, Prihartini Widiyanti, Yurituna Firda
Introduction: Stroke remains a leading cause of disability and death globally, with carotid stenosis as a major contributor. Carotid endarterectomy with patch angioplasty reduces restenosis risk, but current patch materials often lack biocompatibility and biodegradability. This study introduces a novel vascular patch composed of poly-L-lactic acid (PLLA) and chitosan, coated with heparin, designed to promote tissue integration and safe degradation.
Method: A true experimental in vivo study was conducted using 54 Wistar rats, divided into three groups: (1) PLLA scaffold (Group K1/K2), (2) PLLA-chitosan scaffold (Group P1/P3), and (3) PLLA-chitosan with heparin coating scaffold (Group P2/P4). Histological analyses at 14 and 56 days post-implantation evaluated inflammatory response, fibrous capsule formation, and angiogenesis. Statistical analysis included ANOVA, T-test, and Mann-Whitney U test (significance p < 0.05).
Results: At 14 days, inflammatory cell infiltration differed significantly among groups (p = 0.019), with the PLLA-chitosan patch showing the lowest inflammatory cell count. By 56 days, inflammation had subsided in all groups (p = 0.989). Initial fibrous capsule thickness at 14 days was higher in the heparin-coated group and differed significantly among groups (p = 0.019), but by 56 days all groups showed stable fibrous encapsulation with no significant differences (p = 0.916). All implants supported neovascularization, with evidence of new blood vessel formation (angiogenesis) around the patch materials. No excessive fibrous tissue formation or cytotoxic effects were observed in any group.
Conclusion: The heparin-coated PLLA-chitosan patch displayed good biocompatibility, modulating inflammation, and supporting neovascularization. These findings suggest its potential as a vascular graft for large vessel reconstruction, though further long-term studies are needed.
{"title":"Biocompatibility of heparin-coated PLLA-chitosan patch potentially usable for large blood vessel reconstruction: A Wistar rat histological study.","authors":"Yusriandi Ramadhan, Rahadian Indarto Susilo, Nur Setiawan Suroto, Dyah Fauziah, Asra Al Fauzi, Achmad Fahmi, Prihartini Widiyanti, Yurituna Firda","doi":"10.1177/03913988251409049","DOIUrl":"10.1177/03913988251409049","url":null,"abstract":"<p><strong>Introduction: </strong>Stroke remains a leading cause of disability and death globally, with carotid stenosis as a major contributor. Carotid endarterectomy with patch angioplasty reduces restenosis risk, but current patch materials often lack biocompatibility and biodegradability. This study introduces a novel vascular patch composed of poly-L-lactic acid (PLLA) and chitosan, coated with heparin, designed to promote tissue integration and safe degradation.</p><p><strong>Method: </strong>A true experimental in vivo study was conducted using 54 Wistar rats, divided into three groups: (1) PLLA scaffold (Group K1/K2), (2) PLLA-chitosan scaffold (Group P1/P3), and (3) PLLA-chitosan with heparin coating scaffold (Group P2/P4). Histological analyses at 14 and 56 days post-implantation evaluated inflammatory response, fibrous capsule formation, and angiogenesis. Statistical analysis included ANOVA, <i>T</i>-test, and Mann-Whitney <i>U</i> test (significance <i>p</i> < 0.05).</p><p><strong>Results: </strong>At 14 days, inflammatory cell infiltration differed significantly among groups (<i>p</i> = 0.019), with the PLLA-chitosan patch showing the lowest inflammatory cell count. By 56 days, inflammation had subsided in all groups (<i>p</i> = 0.989). Initial fibrous capsule thickness at 14 days was higher in the heparin-coated group and differed significantly among groups (<i>p</i> = 0.019), but by 56 days all groups showed stable fibrous encapsulation with no significant differences (<i>p</i> = 0.916). All implants supported neovascularization, with evidence of new blood vessel formation (angiogenesis) around the patch materials. No excessive fibrous tissue formation or cytotoxic effects were observed in any group.</p><p><strong>Conclusion: </strong>The heparin-coated PLLA-chitosan patch displayed good biocompatibility, modulating inflammation, and supporting neovascularization. These findings suggest its potential as a vascular graft for large vessel reconstruction, though further long-term studies are needed.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"47-54"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-06DOI: 10.1177/03913988251398851
Ahmed M El Banayosy, Joseph M Brewer, Luke C Cunningham, David W Vanhooser, Marshall T Bell, Kaitlyn Cain, Laura V Swant, Jordan Phillips, Obaid Ashraf, Aly El Banayosy, Robert S Schoaps, Mircea R Mihu
Background: Cardiogenic shock (CS) secondary to acute decompensated heart failure (ADHF) is a life-threatening condition that may require the use of mechanical circulatory support (MCS). Venoarterial (VA) extracorporeal membrane oxygenation (ECMO) represents one of the first-line temporary MCS options.
Methods: We conducted a single-center, retrospective observational cohort study of adult patients with CS secondary to ADHF that required VA ECMO at our institution from 2014 to 2023. Patients requiring extracorporeal cardiopulmonary resuscitation (ECPR) or initially placed on venovenous (VV) ECMO were excluded. Baseline characteristics, ECMO support details, and clinical outcomes were analyzed. The primary outcomes were survival to hospital discharge and at 2 years.
Results: A total of 69 patients were included. The median age was 55 years old and 60.9% were male. All patients were cannulated peripherally, with a median duration of support of 10 days. ECMO weaning was achieved in 73.9% and 56.5% survived to hospital discharge. The 2-year survival rate was 46.3%. From the total number of patients, 36.2% were bridged to durable MCS, 16% were weaned and survived to discharge, and 13% underwent heart transplantation. The most common complications included renal replacement therapy (34.8%), bleeding (20.3%), and infection (16%). Notable complications that were associated with worse outcomes included neurologic events, bleeding complications, and renal replacement requirement.
Conclusion: In patients with ADHF-CS, VA ECMO is a viable short-term support strategy that facilitates bridging to recovery or advanced therapies.
{"title":"Extracorporeal membrane oxygenation for acute decompensated heart failure: Encouraging long term outcomes.","authors":"Ahmed M El Banayosy, Joseph M Brewer, Luke C Cunningham, David W Vanhooser, Marshall T Bell, Kaitlyn Cain, Laura V Swant, Jordan Phillips, Obaid Ashraf, Aly El Banayosy, Robert S Schoaps, Mircea R Mihu","doi":"10.1177/03913988251398851","DOIUrl":"10.1177/03913988251398851","url":null,"abstract":"<p><strong>Background: </strong>Cardiogenic shock (CS) secondary to acute decompensated heart failure (ADHF) is a life-threatening condition that may require the use of mechanical circulatory support (MCS). Venoarterial (VA) extracorporeal membrane oxygenation (ECMO) represents one of the first-line temporary MCS options.</p><p><strong>Methods: </strong>We conducted a single-center, retrospective observational cohort study of adult patients with CS secondary to ADHF that required VA ECMO at our institution from 2014 to 2023. Patients requiring extracorporeal cardiopulmonary resuscitation (ECPR) or initially placed on venovenous (VV) ECMO were excluded. Baseline characteristics, ECMO support details, and clinical outcomes were analyzed. The primary outcomes were survival to hospital discharge and at 2 years.</p><p><strong>Results: </strong>A total of 69 patients were included. The median age was 55 years old and 60.9% were male. All patients were cannulated peripherally, with a median duration of support of 10 days. ECMO weaning was achieved in 73.9% and 56.5% survived to hospital discharge. The 2-year survival rate was 46.3%. From the total number of patients, 36.2% were bridged to durable MCS, 16% were weaned and survived to discharge, and 13% underwent heart transplantation. The most common complications included renal replacement therapy (34.8%), bleeding (20.3%), and infection (16%). Notable complications that were associated with worse outcomes included neurologic events, bleeding complications, and renal replacement requirement.</p><p><strong>Conclusion: </strong>In patients with ADHF-CS, VA ECMO is a viable short-term support strategy that facilitates bridging to recovery or advanced therapies.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"39-46"},"PeriodicalIF":1.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-19DOI: 10.1177/03913988251392005
Amnuay Kleebayoon, Viroj Wiwanitkit
{"title":"RE: Association of exposure below various thresholds of hemodynamic parameters during cardiopulmonary bypass with acute kidney injury.","authors":"Amnuay Kleebayoon, Viroj Wiwanitkit","doi":"10.1177/03913988251392005","DOIUrl":"10.1177/03913988251392005","url":null,"abstract":"","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"867-868"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-20DOI: 10.1177/03913988251391992
Rui-Kun Li, Tao Feng, Xue Zhang
Objective: This study aimed to investigate the impact of different ultrafiltration (UF) volumes (UFVs) during haemodialysis (HD) on cardiac function and myocardial work (MW) indices in patients with kidney failure (KF) undergoing maintenance HD (MHD).
Methods: A total of 58 participants were enrolled. The patients with KF were stratified into two groups based on their UFV. Data were collected between July 2023 and August 2024 at the Second Affiliated Hospital of Baotou Medical College. Cardiac parameters were measured using echocardiography before and after HD.
Results: Compared with healthy controls, the KF groups exhibited significantly elevated systolic blood pressure, heart rate and early diastolic mitral inflow velocity to early diastolic mitral annulus velocity ratio, along with reduced global longitudinal strain (GLS), global work efficiency (GWE), global constructive work (GCW) and global work index (GWI; all p < 0.05). Post-HD, the ⩽3% group showed improvements in GLS and GWE, whereas GCW, global wasted work and GWI decreased significantly (p < 0.05). In contrast, the >3% group experienced reductions in left atrial and ventricular size, GCW, GWE and GWI following dialysis (p < 0.05), without significant changes in GLS.
Conclusion: Ultrafiltration volumes during HD significantly affect MW and cardiac function. Ultrafiltration ⩽3% of dry weight appears to mitigate the adverse impact on cardiac parameters, offering potential clinical value for optimising HD protocols.
{"title":"Two-dimensional speckle-tracking echocardiography and automated myocardial functional imaging in assessing acute ultrafiltration volume effects on myocardial work.","authors":"Rui-Kun Li, Tao Feng, Xue Zhang","doi":"10.1177/03913988251391992","DOIUrl":"10.1177/03913988251391992","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the impact of different ultrafiltration (UF) volumes (UFVs) during haemodialysis (HD) on cardiac function and myocardial work (MW) indices in patients with kidney failure (KF) undergoing maintenance HD (MHD).</p><p><strong>Methods: </strong>A total of 58 participants were enrolled. The patients with KF were stratified into two groups based on their UFV. Data were collected between July 2023 and August 2024 at the Second Affiliated Hospital of Baotou Medical College. Cardiac parameters were measured using echocardiography before and after HD.</p><p><strong>Results: </strong>Compared with healthy controls, the KF groups exhibited significantly elevated systolic blood pressure, heart rate and early diastolic mitral inflow velocity to early diastolic mitral annulus velocity ratio, along with reduced global longitudinal strain (GLS), global work efficiency (GWE), global constructive work (GCW) and global work index (GWI; all <i>p</i> < 0.05). Post-HD, the ⩽3% group showed improvements in GLS and GWE, whereas GCW, global wasted work and GWI decreased significantly (<i>p</i> < 0.05). In contrast, the >3% group experienced reductions in left atrial and ventricular size, GCW, GWE and GWI following dialysis (<i>p</i> < 0.05), without significant changes in GLS.</p><p><strong>Conclusion: </strong>Ultrafiltration volumes during HD significantly affect MW and cardiac function. Ultrafiltration ⩽3% of dry weight appears to mitigate the adverse impact on cardiac parameters, offering potential clinical value for optimising HD protocols.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"878-890"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145563632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Coupled plasma filtration and adsorption (CPFA) is a non-selective extracorporeal technique designed to modulate systemic inflammation through plasma filtration combined with resin-based adsorption. While preclinical data were promising, randomized trials in septic shock yielded conflicting results and raised safety concerns, leading to its discontinuation. Nonetheless, selected patients might benefit from CPFA when adequately delivered.
Methods: We performed a retrospective, single-center observational study of 36 critically ill patients treated with CPFA between 2019 and 2022. A total of 56 CPFA sessions were analyzed, evaluating clinical indications, plasma-treated volume (VPT), hemodynamic changes, and clinical outcomes.
Results: The main indication was sepsis (75%), followed by rhabdomyolysis and intoxications (8% each). Most patients received one to two sessions, with a mean duration of 9 ± 1 h and a VPT of 10,103 ± 4275 mL. Survival at 72 h and 28 days was 85% and 61%, respectively, with no early deaths. Patients achieving a VPT ⩾18% of estimated plasma volume had better 28-day survival (81% vs 42%, p = 0.03), although they had lower initial severity scores. A non-significant trend toward vasopressor reduction was observed. No major adverse events occurred.
Conclusion: In this cohort, CPFA was feasible and safe, with possible hemodynamic and survival benefits when a sufficient plasma-treated volume was reached. Patient selection and optimized treatment delivery appear crucial. However, the retrospective design and lack of a control group limit definitive conclusions. Future research should focus on more effective and targeted extracorporeal strategies for immune modulation in critically ill patients.
背景:耦合血浆过滤和吸附(CPFA)是一种非选择性体外技术,旨在通过血浆过滤结合树脂吸附来调节全身炎症。虽然临床前数据很有希望,但脓毒性休克的随机试验产生了相互矛盾的结果,并引起了安全性问题,导致其停止使用。尽管如此,经选择的患者在充分使用CPFA时可能会受益。方法:对2019 - 2022年间36例经CPFA治疗的危重患者进行回顾性、单中心观察性研究。共分析56个CPFA疗程,评估临床适应症、血浆处理量(VPT)、血流动力学变化和临床结果。结果:主要指征为败血症(75%),其次为横纹肌溶解和中毒(各占8%)。大多数患者接受一至两次疗程,平均持续时间为9±1小时,VPT为10,103±4275 mL。72 h和28 d存活率分别为85%和61%,无早期死亡。达到VPT小于估计血浆容量18%的患者有更好的28天生存率(81% vs 42%, p = 0.03),尽管他们的初始严重程度评分较低。观察到血管加压素降低的非显著趋势。未发生重大不良事件。结论:在该队列中,CPFA是可行且安全的,当达到足够的血浆处理容量时,可能具有血流动力学和生存益处。患者选择和优化治疗递送显得至关重要。然而,回顾性设计和缺乏对照组限制了明确的结论。未来的研究应该集中在更有效和更有针对性的体外免疫调节策略在危重患者。
{"title":"The last dance of coupled plasma filtration adsorption (CPFA): Clinical outcomes, challenges, and perspectives in multiple organ support therapy.","authors":"Cristian Pedreros-Rosales, Pilar Musalem, Cristóbal Alvarado Livacic, Hans Müller-Ortiz, Gonzalo Ramírez-Guerrero","doi":"10.1177/03913988251391998","DOIUrl":"10.1177/03913988251391998","url":null,"abstract":"<p><strong>Background: </strong>Coupled plasma filtration and adsorption (CPFA) is a non-selective extracorporeal technique designed to modulate systemic inflammation through plasma filtration combined with resin-based adsorption. While preclinical data were promising, randomized trials in septic shock yielded conflicting results and raised safety concerns, leading to its discontinuation. Nonetheless, selected patients might benefit from CPFA when adequately delivered.</p><p><strong>Methods: </strong>We performed a retrospective, single-center observational study of 36 critically ill patients treated with CPFA between 2019 and 2022. A total of 56 CPFA sessions were analyzed, evaluating clinical indications, plasma-treated volume (VPT), hemodynamic changes, and clinical outcomes.</p><p><strong>Results: </strong>The main indication was sepsis (75%), followed by rhabdomyolysis and intoxications (8% each). Most patients received one to two sessions, with a mean duration of 9 ± 1 h and a VPT of 10,103 ± 4275 mL. Survival at 72 h and 28 days was 85% and 61%, respectively, with no early deaths. Patients achieving a VPT ⩾18% of estimated plasma volume had better 28-day survival (81% vs 42%, <i>p</i> = 0.03), although they had lower initial severity scores. A non-significant trend toward vasopressor reduction was observed. No major adverse events occurred.</p><p><strong>Conclusion: </strong>In this cohort, CPFA was feasible and safe, with possible hemodynamic and survival benefits when a sufficient plasma-treated volume was reached. Patient selection and optimized treatment delivery appear crucial. However, the retrospective design and lack of a control group limit definitive conclusions. Future research should focus on more effective and targeted extracorporeal strategies for immune modulation in critically ill patients.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"871-877"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145512694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-18DOI: 10.1177/03913988251391983
Vikram N, Sabeenian Rs
This research introduces a meticulously designed dual-port antenna tailored to operate within the 2.3-2.4 GHz frequency spectrum. The design specifically addresses challenges of achieving high isolation, reducing envelope correlation, and maintaining robust diversity performance in compact multi-antenna systems. The configuration prioritizes optimal performance metrics to meet stringent communication demands. Notably, the isolation between antenna elements surpasses 20 dB, ensuring minimal interference and enhanced signal integrity in diverse communication environments. Achieving impressive radiation performance, the antenna promises robust signal transmission capabilities while adhering to strict power consumption constraints. Its exceptionally low ECC of less than 0.1 contributes to heightened data reliability, crucial in modern communication systems. Moreover, the antenna exhibits a remarkable diversity gain, nearing 10 dB, facilitating improved signal reception and effectively combating fading and multipath propagation. Notably, its measured channel capacity of 8 bps/Hz underscores its potential for high-bandwidth applications. Fabrication and measurement outcomes meticulously align with theoretical projections, confirming successful synchronization between the antenna's designed specifications and real-world performance, validating its practical viability for diverse wireless communication systems.
{"title":"A very compact two-element implantable MIMO antenna for bio-medical applications.","authors":"Vikram N, Sabeenian Rs","doi":"10.1177/03913988251391983","DOIUrl":"10.1177/03913988251391983","url":null,"abstract":"<p><p>This research introduces a meticulously designed dual-port antenna tailored to operate within the 2.3-2.4 GHz frequency spectrum. The design specifically addresses challenges of achieving high isolation, reducing envelope correlation, and maintaining robust diversity performance in compact multi-antenna systems. The configuration prioritizes optimal performance metrics to meet stringent communication demands. Notably, the isolation between antenna elements surpasses 20 dB, ensuring minimal interference and enhanced signal integrity in diverse communication environments. Achieving impressive radiation performance, the antenna promises robust signal transmission capabilities while adhering to strict power consumption constraints. Its exceptionally low ECC of less than 0.1 contributes to heightened data reliability, crucial in modern communication systems. Moreover, the antenna exhibits a remarkable diversity gain, nearing 10 dB, facilitating improved signal reception and effectively combating fading and multipath propagation. Notably, its measured channel capacity of 8 bps/Hz underscores its potential for high-bandwidth applications. Fabrication and measurement outcomes meticulously align with theoretical projections, confirming successful synchronization between the antenna's designed specifications and real-world performance, validating its practical viability for diverse wireless communication systems.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"904-911"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145549277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-18DOI: 10.1177/03913988251385486
Thomas Auen, Laura Lienemann, Adam Burdorf, Scott W Lundgren, Stanley Radio
As a surgical treatment option for heart failure, left ventricular assist devices (LVAD) help to restore function in failing hearts. Recent studies suggest possible negative impacts of this therapy, as LVAD reduces blood flow and allows potential for coronary remodeling and increased intimal alteration. Our study examined patients with clinically diagnosed non-ischemic cardiomyopathy (NICM) and subsequent heart failure necessitating transplantation and the use of LVAD as a bridge to transplant. Surgically explanted heart specimens were identified and both semi-quantitatively scored and quantitatively assessed for the degree of cross-sectional coronary artery luminal narrowing. Non-parametric statistical analysis of semi-quantitative scored cases was conducted to examine differences between the test population and a control population of NICM patients undergoing transplant without the use of LVAD bridge to therapy. Parametric analysis of the quantitative digitally assessed cases was conducted to corroborate these results. The test population demonstrated a statistically significant difference in coronary artery luminal narrowing compared to the control population. Our findings suggest increased coronary artery disease in previous NICM patients receiving LVAD as a bridge to transplantation regardless of the time with the implanted device. Further work is necessary for future correlation, as these findings bear importance for improving transplant patient outcomes.
{"title":"The effect of left ventricular assist devices on the propagation of coronary artery disease in explanted hearts.","authors":"Thomas Auen, Laura Lienemann, Adam Burdorf, Scott W Lundgren, Stanley Radio","doi":"10.1177/03913988251385486","DOIUrl":"10.1177/03913988251385486","url":null,"abstract":"<p><p>As a surgical treatment option for heart failure, left ventricular assist devices (LVAD) help to restore function in failing hearts. Recent studies suggest possible negative impacts of this therapy, as LVAD reduces blood flow and allows potential for coronary remodeling and increased intimal alteration. Our study examined patients with clinically diagnosed non-ischemic cardiomyopathy (NICM) and subsequent heart failure necessitating transplantation and the use of LVAD as a bridge to transplant. Surgically explanted heart specimens were identified and both semi-quantitatively scored and quantitatively assessed for the degree of cross-sectional coronary artery luminal narrowing. Non-parametric statistical analysis of semi-quantitative scored cases was conducted to examine differences between the test population and a control population of NICM patients undergoing transplant without the use of LVAD bridge to therapy. Parametric analysis of the quantitative digitally assessed cases was conducted to corroborate these results. The test population demonstrated a statistically significant difference in coronary artery luminal narrowing compared to the control population. Our findings suggest increased coronary artery disease in previous NICM patients receiving LVAD as a bridge to transplantation regardless of the time with the implanted device. Further work is necessary for future correlation, as these findings bear importance for improving transplant patient outcomes.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"891-896"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145312853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-19DOI: 10.1177/03913988251392008
Takumi Sasaki, Toshiyuki Nakanishi, Kazuya Sobue
{"title":"Response to: RE: Association of exposure below various thresholds of hemodynamic parameters during CPB with acute kidney injury.","authors":"Takumi Sasaki, Toshiyuki Nakanishi, Kazuya Sobue","doi":"10.1177/03913988251392008","DOIUrl":"10.1177/03913988251392008","url":null,"abstract":"","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"869-870"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-20DOI: 10.1177/03913988251392010
Salih Düzgün, Mehmet Çiçek, Büşranur Yavuz, Hüseyin Sinan Topçuoğlu, İpek Eraslan Akyüz
This study aimed to evaluate the efficacy of different irrigation activation systems in removing calcium hydroxide from simulated internal resorption cavities using standardized Three-Dimensional (3D) printed root canal models and objective volumetric analysis. A maxillary central incisor was scanned via micro-computed tomography and reconstructed to create standardized 3D-printed teeth with simulated internal resorption cavities. Sixty-four samples were divided into four groups (n = 16) according to the irrigation method: Conventional Needle Irrigation (CNI), Irrigation Ultrasonic Agitation (IUA), EndoActivator (EA), and XP-endo Finisher (XPF). Following calcium hydroxide placement and incubation, different irrigation protocols were applied. Residual calcium hydroxide volume was assessed using CBCT imaging and segmented with 3D Slicer software. Statistical analysis was performed with one-way ANOVA and Dunnett's T3 post-hoc test (α = 0.05). XPF removed significantly more calcium hydroxide than CNI and EA (p < 0.05). No statistically significant difference was found between XPF and IUA. None of the tested activation systems, except for one specimen in the IUA group, completely removed the calcium hydroxide from simulated internal resorption cavities. XPF removed significantly more calcium hydroxide than CNI and EA, while XPF and IUA exhibited similar performance.
{"title":"Efficacy of activation systems in removing calcium hydroxide from 3D printed internal resorption cavities: a new study design.","authors":"Salih Düzgün, Mehmet Çiçek, Büşranur Yavuz, Hüseyin Sinan Topçuoğlu, İpek Eraslan Akyüz","doi":"10.1177/03913988251392010","DOIUrl":"10.1177/03913988251392010","url":null,"abstract":"<p><p>This study aimed to evaluate the efficacy of different irrigation activation systems in removing calcium hydroxide from simulated internal resorption cavities using standardized Three-Dimensional (3D) printed root canal models and objective volumetric analysis. A maxillary central incisor was scanned via micro-computed tomography and reconstructed to create standardized 3D-printed teeth with simulated internal resorption cavities. Sixty-four samples were divided into four groups (<i>n</i> = 16) according to the irrigation method: Conventional Needle Irrigation (CNI), Irrigation Ultrasonic Agitation (IUA), EndoActivator (EA), and XP-endo Finisher (XPF). Following calcium hydroxide placement and incubation, different irrigation protocols were applied. Residual calcium hydroxide volume was assessed using CBCT imaging and segmented with 3D Slicer software. Statistical analysis was performed with one-way ANOVA and Dunnett's T3 post-hoc test (α = 0.05). XPF removed significantly more calcium hydroxide than CNI and EA (<i>p</i> < 0.05). No statistically significant difference was found between XPF and IUA. None of the tested activation systems, except for one specimen in the IUA group, completely removed the calcium hydroxide from simulated internal resorption cavities. XPF removed significantly more calcium hydroxide than CNI and EA, while XPF and IUA exhibited similar performance.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"897-903"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145563660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-11-03DOI: 10.1177/03913988251373000
Joanne A Pagaduan, Don Eliseo Lucero-Prisno, Jomar L Aban
{"title":"Biological intelligence in device design: A breakthrough path to hemocompatibility via synthetic embryoids.","authors":"Joanne A Pagaduan, Don Eliseo Lucero-Prisno, Jomar L Aban","doi":"10.1177/03913988251373000","DOIUrl":"10.1177/03913988251373000","url":null,"abstract":"","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"803-805"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}